REGN7041
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Active Noninfectious Uveitis Affecting the Posterior Segment
Conditions
Active Noninfectious Uveitis Affecting the Posterior Segment
Trial Timeline
Dec 17, 2025 → Jun 28, 2028
NCT ID
NCT07218770About REGN7041
REGN7041 is a phase 1/2 stage product being developed by Regeneron Pharmaceuticals for Active Noninfectious Uveitis Affecting the Posterior Segment. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07218770. Target conditions include Active Noninfectious Uveitis Affecting the Posterior Segment.
What happened to similar drugs?
20 of 20 similar drugs in Active Noninfectious Uveitis Affecting the Posterior Segment were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07218770 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Active Noninfectious Uveitis Affecting the Posterior Segment